BusinessVBI Vaccines Announces First Quarter 2018 Financial Results and Provides Corporate UpdateBy Nasdaq OMXMay 1, 2018, 12:01 PM UTC
BusinessVBI Vaccines Announces Completion of Enrollment in PROTECT Phase 3 Clinical Study for Sci-B-Vac® Hepatitis B VaccineBy Nasdaq OMXApr 19, 2018, 12:00 PM UTC
BusinessVBI Vaccines Announces Initiation of Phase 3 Clinical Program for Sci-B-Vac® Hepatitis B VaccineBy Nasdaq OMXDec 19, 2017, 1:00 PM UTC
BusinessVBI Vaccines to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare ConferenceBy Nasdaq OMXDec 12, 2017, 1:00 PM UTC
BusinessVBI Vaccines Announces Closing of Public Offering and Concurrent Registered Direct Offering of Common SharesBy Nasdaq OMXOct 31, 2017, 12:31 PM UTC
BusinessVBI Vaccines Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares and Upsized Registered Direct Offering for Aggregate Proceeds of $71.9 MillionBy Nasdaq OMXOct 30, 2017, 12:01 PM UTC
BusinessVBI Vaccines Prices Concurrent Public Offering and Registered Direct Offering for Aggregate Proceeds of $63.5 MillionBy Nasdaq OMXOct 26, 2017, 1:29 PM UTC
BusinessVBI Vaccines Announces Proposed Concurrent Public Offering and Registered Direct Offering of Common SharesBy Nasdaq OMXOct 25, 2017, 8:01 PM UTC
